Literature DB >> 15003644

A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.

Tuhina Mazumdar1, Khairul Anam, Nahid Ali.   

Abstract

In this study, we have developed a vaccine with Leishmania donovani promastigote membrane antigens (leishmanial antigens (LAg)) encapsulated in a liposome carrier formulated with distearyol (DSPC, transition temperature (Tc) = 54 degrees C) derivative of l-alpha-phosphatidyl choline, for immunizing BALB/c mice against progressive visceral leishmaniasis. This formulation could limit hepatosplenomegaly to almost normal levels and conferred strong levels of protection in both liver and spleen against challenge infection. Immunization with liposomal LAg activated peritoneal macrophages for enhanced leishmanicidal activity in association with NO production, and induced antibody as well as T-cell mediated immune responses. Production of both IFN-gamma and IL-4 by splenic T cells, and serum IgG1 and IgG2a, suggest induction of a mixed Th1/Th2 response following immunization. Experimental challenge corresponded with elevated DTH, and mitogen and antigen specific cellular responses. Increased production of NO and IFN-gamma by spleen cells, and down regulation of IL-4, demonstrate that an initial stimulation of a mixed Th1/Th2 response by vaccination instructs Th1 responses and resistance against a progressive infection by L. donovani.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003644     DOI: 10.1016/j.vaccine.2003.09.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

2.  Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.

Authors:  J B Knight; Y Y Huang; S A Halperin; R Anderson; A Morris; A Macmillan; T Jones; D S Burt; G Van Nest; S F Lee
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

3.  Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.

Authors:  Blaise Dondji; Eva Pérez-Jimenez; Karen Goldsmith-Pestana; Mariano Esteban; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response.

Authors:  Rady J Laborde; Oraly Sanchez-Ferras; María C Luzardo; Yoelys Cruz-Leal; Audry Fernández; Circe Mesa; Liliana Oliver; Liem Canet; Liane Abreu-Butin; Catarina V Nogueira; Mayra Tejuca; Fabiola Pazos; Carlos Álvarez; María E Alonso; Ieda M Longo-Maugéri; Michael N Starnbach; Darren E Higgins; Luis E Fernández; María E Lanio
Journal:  J Immunol       Date:  2017-03-03       Impact factor: 5.422

5.  Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to leishmania donovani infection but develop severe liver immunopathology.

Authors:  Lucia E Rosas; Anjali A Satoskar; Kimberly M Roth; Tracy L Keiser; Joseph Barbi; Christopher Hunter; Frederic J de Sauvage; Abhay R Satoskar
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

6.  Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.

Authors:  Rajesh Ravindran; Sudipta Bhowmick; Amrita Das; Nahid Ali
Journal:  BMC Microbiol       Date:  2010-06-24       Impact factor: 3.605

7.  Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice.

Authors:  Jianhua Sun; Xiaoming Song; Songhua Hu
Journal:  Clin Vaccine Immunol       Date:  2007-12-19

8.  gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Authors:  Swati Bhowmick; Rajesh Ravindran; Nahid Ali
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

9.  Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection.

Authors:  Sudipta Bhowmick; Tuhina Mazumdar; Nahid Ali
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

10.  Mimetic membrane system to carry multiple antigenic proteins from Leishmania amazonensis.

Authors:  Fabiana R Santos; Denise B Ferraz; Katia R P Daghastanli; F Juarez Ramalho-Pinto; Pietro Ciancaglini
Journal:  J Membr Biol       Date:  2006-08-14       Impact factor: 2.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.